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ARTICLE
Direct quality control of glycoengineered
erythropoietin variants
Tomislav Čaval 1,2, Weihua Tian 3, Zhang Yang 3, Henrik Clausen 3 & Albert J.R. Heck 1,2
Recombinant production of glycoprotein therapeutics like erythropoietin (EPO) in mammalian
CHO cells rely on the heterogeneous N-glycosylation capacity of the cell. Recently,
approaches for engineering the glycosylation capacities of mammalian cells for custom
designed glycoforms have been developed. With these opportunities there is an increasing
need for fast, sensitive, and global analysis of the glycoproteoform landscape produced to
evaluate homogeneity and consistency. Here we use high-resolution native mass spectro-
metry to measure the glycoproteoform proﬁle of 24 glycoengineered variants of EPO. Based
on the unique mass and intensity proﬁles of each variant, we classify them according to
similarities in glycosylation proﬁles. The classiﬁcation distinguishes EPO variants with varying
levels of glycan branchingand sialylation, which are crucial parameters in biotherapeutic
efﬁcacy. We propose that our methods could be of great beneﬁt in the characterization of
other glycosylated biopharmaceuticals, ranging from the initial clonal selection to batch-to-
batch controls, and the assessment of similarity between biosimilar/biobetter products.
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A large majority of clinically relevant protein-based biolo-gics are glycosylated1. Glycosylation, speciﬁcally N-gly-cosylation, modulates the function of biologics in a variety
of ways. Most notably, lack of a Fucose residue on N-glycans in
the Fc domain of IgG molecules signiﬁcantly increase antibody-
dependent cell-mediated cytotoxicity2. Additionally, galactosyla-
tion and sialylation play an important role in complement-
dependent cytotoxicity3 and anti-inﬂammatory activity4, respec-
tively. Moreover, sialylation and increased branching of ery-
thropoietin (EPO) N-glycans increases its serum half-life5,6, while
EPO lacking sialylation exhibits neuroprotective role in vivo7.
Thus, a well-deﬁned view of the detailed glycosylation proﬁle of
biotherapeutics is essential.
To ensure optimal efﬁcacy and safety of biotherapeutics,
human-like glycosylation with clearly deﬁned glycoforms can be
beneﬁcial. For this reason, biologics are so far mostly expressed in
Chinese hamster ovary (CHO) cells capable of human-like gly-
cosylation1. However, CHO cells produce quite heterogeneous
N-glycans on recombinant glycoproteins and also lack the capa-
city for producing the human-like α2,6-linked sialic acid glyco-
form. Thus, obtaining a homogenous biotherapeutic product
with desirable glycan features remains a challenge. To address
this need various glycoengineering approaches have been devel-
oped8–13. Attractive emerging strategies include the so-called
GlycoDelete approach wherein complex N-glycans are reduced to
trisaccharide stems10,11, and a second approach wherein combi-
natorial knock out (KO) and knock in (KI) of various glycosyl-
transferase enzymes in CHO are used to create a cell with custom
designed glycosylation capacity to produce a more homogenous
glycosylation proﬁle8,14(Fig. 1a).
With biologics displaying such a complex glycosylation proﬁle,
an issue that needs to be addressed is the in-detail analytical
assessment of the glycoproteoform heterogeneity. This is of spe-
cial importance when a deﬁned glycoproﬁle is required for a
proper biological activity. In addition to that, looming patent
expiry of almost all “blockbuster” biotherapeutics, will open
avenues for opportunities in creation of biosimilars and/or bio-
better biologics, that need to be structurally and functio-
nally evaluated in comparison to their corresponding
originals1,15,16.
A direct assessment of the structural similarity may come from
the high-resolution mass measurement of the glycoprotein of
interest in its intact form. However, even for IgGs, that express
typically a relatively simple glycosylation proﬁle, measuring under
standard reducing MS conditions will not provide a complete
picture of glycoproteoform heterogeneity13. This issue was par-
tially addressed with the introduction of an Orbitrap mass ana-
lyzer with extended mass range (Orbitrap EMR)17. The Orbitrap
EMR enabled high-resolution mass spectrometry (MS) mea-
surements of intact IgG glycoproteoforms under non-denaturing/
native conditions18. What makes native MS attractive for IgG
analysis is the simplicity of the resulting spectra and efﬁcient
analysis, which can typically be done under an hour19. Further-
more, when benchmarked against more standard glycomics
approach, glycoproteoform proﬁling of intact IgGs by native MS
performed qualitatively as well as quantitatively very well20.
However, the complexities with glycoproteins having multiple
glycosites and both N and O-linked glycans have so far not been
overcome, although great strides towards this goal have been
achieved21. Here, we approach EPO22, which is one of the most
used therapeutic biologics today and has a complex and hetero-
geneous glycoprotein with three N-glycans and one O-glycan23.
When compared to the relatively simple native MS spectra for
therapeutic IgGs that typically display only a dozen of different
glycoforms, the EPO native MS spectra exhibit hundreds of dif-
ferent glycoproteoforms22 arising from the heterogeneity on its
three N- and one O-glycosylation sites. This makes compositional
analysis of such spectra much more challenging.
Here we explore and demonstrate the applicability of native
MS for the structural characterization of engineered variants of
EPO with diverse patterns of N-glycans. We used a panel of
glycoengineered CHO cells to express EPO with different gly-
cosylation features and degrees of heterogeneity to dissect and
validate the native MS spectra. For this purpose, we targeted 24
differentially glycoengineered EPOs, all expressed in CHO cells.
The observed glycosylation proﬁles of the glycoengineered
EPOs reveal the co-occurrence of hundreds of variants, which
show a stepwise decrease in heterogeneity as we progress
through our glycoengineering scheme—from heterogeneous,
tetra-antennary, polyLacNAc elongated N-glycans all the way
to homogenous, bi-antennary, non-elongated, and non-
sialylated N-glycans. We demonstrate the potential of native
MS, and ﬁrst fully assign the complex glycosylation proﬁle of
wild-type (WT) EPO. For illustrative purposes, we next focused
on the in-depth analysis of two engineered EPO variants, i.e.
the mgat5 KO and the stacked KO of mgat4A and mgat4B.
Although both these clones express tri-antennary dominated N-
glycan proﬁles, albeit with different branch points, our data
reveal clear differences, whereby the mgat4A/4B KO clone
exhibits a much more complicated glycoproﬁle, originating
from a substantial increase of polyLacNAc extensions, revealing
that native MS is capable of distinguishing close isomeric
conﬁgurations of triantennary N-glycans.
Finally, focusing on all analyzed 24 EPO variants we introduce
a classiﬁcation scheme, based on the acquired native MS spectral
ﬁngerprints. We demonstrate that just by comparing native mass
spectra a product similarity matrix can be created. Using hier-
archical clustering we can directly differentiate glycoengineered
EPO clones, and extract what the gross structural differences are.
In this matrix, we distinguish discrete clusters of 2-, 3-, 4-
antennary modiﬁed EPOs, and clusters exhibiting high and low
sialylated EPO variants. Our approach for classiﬁcation, and
biosimilarity scoring, is generic and could beneﬁt the character-
ization of other glycosylated proteins, clonal selection in cell line
development, and be used for batch-to-batch quality control (QC)
of the glycoproteoform proﬁles and assessment of structural
aspects linked to biosimilarity.
Results
Characterization of WT EPO glycoproteoform proﬁle. Most
glycoengineered EPO clones in our study were designed to reduce
glycoproteoform heterogeneity compared to the non-
glycoengineered CHO-cell produced wild type (WT) EPO.
Therefore, in principle the WT EPO sample should provide the
most complex glycosylation proﬁle. Thus, we ﬁrst attempted to
analyze and assign as many structural variants in WT EPO, based
on the acquired high-resolution native MS data. The acquired
native MS data on WT EPO were in line with previously pub-
lished data on commercially available recombinant EPO var-
iants22. To illustrate the description of our EPO assignments we
display in Fig. 1b a graphic representation of one of the most
abundant WT EPO glycoforms. Depicted are 3 tetra-antennary
N-glycans and one O-glycan (T structure, Galβ1-3GalNAc) that
together result in a total glycan composition of Hex22Hex-
NAc19Fuc3 (using standard nomenclature24) and 14 sialic acids
(sia)—which is the maximum amount of sia moieties a single
EPO molecule can contain. Any further increase in HexHexNAc
content stems from the elongation of one of the antennae in a
process termed poly-N-acetyllactosamine (LacNAc) elongation.
In the “zero-charge” deconvoluted native mass spectrum of WT
EPO (Fig. 1c top) we see that the Mw distribution of EPO
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glycoproteoforms ranges from 29,000 up to almost 34,000 Da.
This 5000 Da spread is caused by differential glycosylation where
the main glycan compositions correspond to a generic compo-
sition of Hexx+3HexNAcxFuc3Siay, wherein 15 < x < 22, and 7 < y
< 14. The most abundant glycoproteoform contains Hex22Hex-
NAc19Fuc3, as depicted in Fig. 1b, albeit containing 12 instead of
14 sia moieties. Additionally, we observed other glycoproteoforms
on WT EPO that are further modiﬁed by polyLacNAc elongation
(Hex23-25HexNAc20-22Fuc3Sia7-14), and/or sequential losses of 1 to
4 of N-glycan branches (Hex18-21HexNAc15-18Fuc3Sia7-13),
resulting in a mixture of bi-, tri-, and tetra-antennary N-glycans.
Evidently, there is always a possibility of multiple isobaric species
present within the same narrow mass window. For instance, the
Hex22HexNAc19Fuc3 composition could correspond to 3 tetra-
antennary N-glycans and an O-glycan, but the same composition
could also represent 1 tetra-antennary N-glycan, 2 polyLacNAc
elongated tri-antennary N-glycans and no O-glycan. To tackle
this issue and probe the possible presence of isobaric species
within each signal we inspected the native MS spectrum of the
B3gnt2 KO that is responsible for polyLacNAc elongation in
CHO cells8 (Supplementary Fig. 1b). In the native MS spectrum
of EPO extracted from clone C16 (B3gnt2 KO), we were surprised
to see that each of the Hex18-21HexNAc15-18Fuc3 glycoproteo-
forms remained almost identical to that of the WT EPO indi-
cating that each of these glycoproteoforms stems predominantly
from the loss of one of the branches on the N-glycans. On the
other hand, we observed the complete disappearance of glyco-
proteoform compositions containing Hex23-25HexNAc20-22Fuc3
when compared to WT EPO, indicating that these compositions
in WT EPO are indeed polyLacNAc elongated.
From the frequently observed Δm-shift of 291 Da it is
apparent that a major factor in EPO glycoproteoform diversity
is differential sialylation. On average, in EPO each Hexx
+3HexNAcxFuc3 composition exhibits 6 different states of
sialylation, with compositions carrying 11 and 12 sialic acid
moieties representing the most abundant variants. To reduce the
heterogeneity, we treated WT EPO with a broad speciﬁcity
sialidase enzyme and reanalyzed that sample by native MS
(Supplementary Fig. 1c). Inspection of this, much less dense,
mass spectrum facilitated the assignment of 12 distinct Hexx
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Fig. 1 Generation and structural assessment of wild type and glyco-engineered EPO. a Depiction of the workﬂow used in this study. EPO is overexpressed in
CHO cells whereby speciﬁc glyco-genes are manipulated to achieve the desired glycosylation, followed by EPO puriﬁcation and native MS analysis. High-
resolution native MS spectra of different clones are correlated, leading to a similarity matrix. b Depiction of EPO glycosylation sites. c Deconvoluted high-
resolution native mass spectra of WT EPO (top) and two KO-based glyco-engineered clones: C23 (middle) and C21 (bottom). These two KO clones would
supposedly delete β-4 and β-6branching of N-glycans as indicated by the pictograms. In these deconvoluted spectra the main glycoproteoforms are color
coded, wherein each color corresponds to a unique Hexx+3HexNAcxF3 composition, where F denotes fucose, and the numbers placed above the annotated
peaks indicate the number of sialic acid residues. d Comparison of native mass spectra of EPO from two biological replicate clones C18 (black) and C19
(orange).The correlation coefﬁcient between these two spectra over all ion signals is 0.93, as depicted in the top-right. All other high-resolution native
mass spectra of EPO, puriﬁed from each of the prepared 25 clones, are provided in Supplementary Fig 4
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+3HexNAcxFuc3 (x= 14–25) glycan compositions, 6 additional
glycoproteoforms with additional HexNAc moieties, and 6
glycoproteoforms with Δm= 80 Da adducts. Although we
cannot distinguish sulfation and phosphorylation directly from
our native mass spectra (Δm= 0,00951 Da), based on the
biosynthetic pathways of N-glycans and previous studies25,26
the 80 Da adducts most likely originate from sulfation. Evidently,
all these structural variants are also present in the non-sialidase
treated WT EPO sample. However, due to heterogeneous
sialylation present in the untreated sample their annotation
becomes more ambiguous and requires additional levels of
analysis, such as we do here by pre-treating WT EPO with
sialidase. Finally, based on the EPO data from the B3gnt2 KO
clone and the sialidase treatment, we could extract that the
maximum sialylation of each Hexx+3HexxNAcFuc3 glycan is
indicative of its N-glycan branching. For instance, Hex22Hex19-
NAcFuc3 has a maximum sialic acid content of 14 indicating the
presence of three tetra-antennary N-glycans. Upon the loss on
one HexHexNAc, which translates into one tri-antennary and
two tetra-antennary N-glycans the maximum number of sialic
acid should be 13, and indeed the composition of Hex21Hex-
NAc18NAcFuc3 does contain a maximum of 13 sialic acid acid
moieties. In agreement, if we inspect the Hex20HexNAc17NAc-
Fuc3 peak, we observe its glycan distribution ends at 12 sialic acid
moieties indicating the presence of yet another tri-antennary N-
glycan.
Glycoproteoform proﬁles of individual glycoengineered EPO’s.
Following the detailed analysis and assignments of structural
features observed in WT EPO, we next focused on the high-
resolution native MS data of all variants. To describe how indi-
vidual KOs and KIs affect the overall EPO glycoproteome proﬁle,
we describe in detail two examples, namely C21 EPO, which
represents a KO for the β1,6-N-acetyl-glucosaminyltransferase
(mgat5) involved in the β6-branching of N-glycans, and C23
EPO, which represents a stacked KO of the β1,4-N-acet-
ylglucosaminyltransferase isozymes A and B (mgat4A/4B) that
control the β4-branching of N-glycans. Because both KO clones
express triantennary glycans8, we hypothesized that the resulting
EPO glycoproteoform proﬁles would look similar. The decon-
voluted native MS spectra are displayed in Fig. 1c middle and
bottom spectra, for the mgat4A/4B KO and mgat5 KO, respec-
tively. Comparing these spectra with each other, but also with the
spectrum obtained for WT EPO (Fig. 1c top), it is directly evident
that the KO of mgat5 results in a more simpliﬁed spectrum for
EPO when compared to mgat4A/4B and WT EPO. Through
spectral inspection and annotation, using the same reasoning as
presented above for WT EPO, we conclude that the more sim-
pliﬁed glycoproteome proﬁle for mgat5 KO originates from a
substantial decrease in polyLacNAc content (Supplementary
Fig. 2). This can be extracted from the low abundance of the
Hex20HexNAc17Fuc3 variants, which indicates the presence of at
least one polyLacNAc repeat, and complete absence of Hex21-
22HexNAc18-19Fuc3 compositions that are present in both
mgat4A/4B KO and WT EPO. From these observations, we could
conﬁrm that the main acceptor site for polyLacNAc elongation
on N-glycans is speciﬁcally the β6-branch and not the β4-branch.
Additionally, we detected a substantially higher diversity and
degree of sialylation in mgat4A/4B KO EPO, when compared to
mgat5 KO. For instance, the two most abundant glycan
composition in both sets of KOs; Hex19-18HexNAc16-15Fuc3,
harbor anywhere between 3–11 sialic acid moieties in mgat4A/4B
KO, while it contains predominantly just 6–11 sialic acid moieties
in mgat5 KO. This difference may be due to either incomplete
sialylation or the presence of multiple isobaric varieties exhibiting
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Fig. 2 Clustering of glycoengineered EPO clones based on the correlation between their native MS spectra. In Supplementary Table 1 an overview is given
of all 25 clones used, annotating which enzyme(s) was/were knocked-out/knocked-in. Color and size of the circles indicate the similarity between clones
where 1 (full circle, dark blue) represents nearly identical EPO glycoproteoform proﬁles. Clusters boxed by full lines represent clones that share high
similarity in their proﬁles in terms of N-glycan branching, sialylation and O-glycosylation capacity. Cluster expansions within dashed lines represent clones
that display similarity as well as subtle differences in terms of N-glycan sialylation or O-glycosylation capacity. Orange, Green, and Purple boxes represent
EPO clones expressing primarily bi-, tri-, or tetra-antennary N-glycans, respectively. Wild Type EPO is denoted as WT
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the same mass. Considering the above-described analysis of WT
EPO and B3gnt2 KO, we argue that these notable differences are
mainly due to the incomplete sialylation occurring in mgat4A/
4BKO, which is also found with the released N-glycan proﬁling8.
Direct structural assessment of glycoengineered EPO variants.
Detailed analysis of all glycoproteoforms distinguishable in the
high-resolution native mass spectra is laborious and still depen-
dent on manual inspection. However, a signiﬁcant beneﬁt of
native mass spectra is that an integral picture about glycopro-
teoform complexity is obtained within a single spectrum. If we
consider the native mass spectra as simple barcodes for EPO
produced by each clone, we could signiﬁcantly accelerate data
analysis of novel clones by just ﬁnding the most similar clone in a
larger set of annotated spectra. Moreover, if one uses the same
clone in a batch mode and wants to ensure the product con-
sistency, the native MS spectra can provide a similarity score used
for QC22. To test the reproducibility of the native MS spectral
readout we measured and compared EPO produced by the C18
and C19 clones (Fig. 1d), being biological replicates, albeit created
and characterized 20 months apart. We observed that EPO pur-
iﬁed from these two clones displays an almost identical glyco-
proteoform pattern, reﬂected by a very high similarity score of
0.93. To illustrate the potential of using the spectral barcodes to
classify glycoengineered EPO variants, we analyzed 25 EPO var-
iants and determined their spectral correlations. Using unsu-
pervised hierarchical clustering we constructed a matrix of all
EPO variants, as shown in Fig. 2. The speciﬁc enzyme KO used in
each clone is listed in Supplementary Table 1 and the full-
unprocessed native MS spectra of all EPO variants are provided in
Supplementary Fig. 4. The clustering led to 5 distinct clusters, and
one extra single clone, which seemingly does not belong to any of
these 5 clusters. The ﬁrst cluster (solid orange box, C04-08)
represents predominantly biantennary sialylated EPO variants. A
slightly more extended cluster (dashed orange lines) includes
additionally C03, which harbors a mixture of mono- and bi-
antennary glycans, and C02 that has an alike N-glycan proﬁle as
C04-08 but carries truncated O-glycans in the form of STn
antigens.
In the second cluster (yellow box), we ﬁnd EPO from 4 clones;
C09-C12, C09 and C10 are biological replicates that express
biantennary N-glycans with reduced sialylation. Interestingly,
they show an increase in polyLacNAc containing glycoproteo-
forms when compared with the C08 clone, which exhibits more
sialylation, indicating that sialylation may limit the extent of
polyLacNAc elongation. C11 and C12 represent a set of biological
replicates that in addition to diminished sialylation carry an
additional KO eliminating polyLacNAc, resulting in an even more
uniform glycoproteform proﬁle. Taken all together this further
demonstrates both the reproducibility of the method as well as
sensitivity to detect the presence of polyLacNAc species.
A third clear cluster (purple box) reveals that wild type EPO
and EPO from clone C17 share almost identical glycoproteoform
proﬁles, which was expected as the B4galt4 KO used in the C17
clone does not have compromised galactosylation capacity for N-
glycans8. EPO from C16, which also falls in this cluster, exhibits a
slight decrease in similarity, largely due to a decrease in
polyLacNAc containing glycoproteoforms. A direct comparison
of the polyLacNAc and sialic acid content of EPO from the two
clones C15 and C16, which display the highest level of
dissimilarity in this cluster, is shown in Supplementary Fig. 3.
Striking differences are found in the amount of sialylation and
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polyLacNAc elongation with EPO from C16 being more
sialylated, while EPO from C15 being more polyLacNAc
elongated. EPO from the other two clones in the same cluster
(C14 and C15), are both KOs of enzymes that do not inﬂuence
glycosylation in CHO cells. This means that we can almost treat
EPO WT, C14-15 and C17 as biological replicates. Indeed, the
subtle differences between these 4 clones are primarily in their
sialylation status. EPO WT and C 17 contain highly sialylated N-
glycans (on average 12 sialic acid moieties per glycoproteoform),
on the other hand EPO from C14 and C15 exhibit a substantially
lower sialylation with on average 8 sialic acid moieties per
glycoproteoform. We hypothesize that a decrease in sialylation of
these two clones is caused by variations during clonal develop-
ment and expansion. Furthermore, the C13 clone, which can be
found in the same, albeit extended cluster (dashed purple lines), is
a KO blocking only core fucosylation. When compared to WT
EPO its glycoproteoform proﬁle is characterized by a −438 Da
mass shift of each observed signal, corresponding to the loss of 3
fucose moieties, which further supports our annotations of WT
EPO in Fig. 1c. Another cluster (red box) contains EPO from the
above described C18 and its biological replicate C19 that contain
tetra-antennary N-glycans with diminished sialylation, and as
such is not expected to show similarity to the purple cluster
containing highly sialylated tetra-antennary N-glycans. This data
reinforces the strength of the method for quality assessment of
EPO produced in different clones and batches.
A ﬁfth cluster (green box) includes EPO from C21 and C23,
which were analyzed in depth, as discussed above (Fig. 1c bottom
and middle), C24, and surprisingly C22. Based on the supposed
combinatorial KOs of the mgat4A/4B/5, st3gal4/6, and cosmc/
C1GALT1 enzymes, C22 was expected to produce EPO with non-
sialylated biantennary N-glycans, and exhibit truncated O-
glycosylation. However, as clearly deduced from the clustering
analysis, the glycoproteoform proﬁle was found to be very similar
to that of C24 EPO, indicating that it was more likely a clone with
KO of mgat4B (see Supplementary Fig. 5). Thus, our initial data
hinted at a possible mix up of samples during some stage of
sample puriﬁcation and handling. Indeed, we could conﬁrm this
by subsequent repeated genotyping of C22 demonstrating that the
EPO sample indeed was derived from a mgat4B KO CHO clone.
Related to this cluster (dashed green lines) EPO from C20 shares
similarity with the other triantennary clones. Again, this can be
rationalized, as C20 should express triantennary N-glycans, with
most differences originating from truncation of O-glycans.
Finally, in our dataset there is a single clone that does not take
part into any of these 5 clusters; C01. The C01 clone is an mgat1
KO and thus expresses only core N-glycans with up to 5 mannose
moieties and limited amounts of core fucosylation, and as such is
not expected to share similarity with any of the other clones
which all express complex type N-glycans.
KO of st3gal4 and st3gal6 does not abolish sialylation.
Although CHO cells produce human-like glycosylation there is
one major difference. The sialic acids, being the outermost sugar
moieties observed on N-glycans are attached via α2-3 linkages in
CHO as opposed to human cells that in addition have attached
α2-6 linkages. Although the direct consequences of this key dif-
ference in linkage on drug performance are not yet known, it is
desirable to produce EPO with all possible human structural
features. We previously reported that the combined KO of
st3gal4/6 essentially abolished sialylation of N-glycans8. This was
based on MALDI-TOF of released permethylated glycans, how-
ever, when we here measured EPO by native MS we were able to
detect low levels of glycoproteoforms with up to 6 sia moieties
(Fig. 3a top and bottom). Interestingly, site-speciﬁc analysis of
these EPO samples by LC-MS/MS also failed to detect the pre-
sence of sialic acids (not shown). Since only 2 out of these 6 sia
moieties could originate from the O-glycan on EPO (Supple-
mentary Fig. 6), the residual 4 sia moieties must originate from N-
glycans. Although double KO of st3gal4/6 clearly decreased the
sialylation levels markedly (Fig. 3b), we could show that it did not
completely eliminate the presence of N-glycan sialylation. This
indicates that additional st3gal’s need to be knocked out to obtain
EPO devoid of sialic acid on N-glycans, and st3gal3 is expressed
in CHO and triple st3gal3/4/6 KO clones have been generated8.
These ﬁndings are further supported by the observation of up to
4 sia moieties in EPO from the C18 clone, shown in in Supple-
mentary Fig. 7, that is also a st3gal4/6 KO, but contains tetra-
antennary N-glycans.
We noticed a −18 Da peak trailing each of the peaks
corresponding to Hex16HexNAc13Fuc3Sia1-4 compositions. This
peak completely disappeared upon sialidase treatment (Fig. 3c),
indicating that the −18 Da peak is caused by a dehydration event
on the sialic acid moiety. Due to the presence of dehydrated peaks
in both biological replicates, corroborated by a recent study27
describing the presence of dehydrated sialic acids in commercially
available bio-therapeutic EPOs we are inclined to believe that this
is not an artefact caused by the ESI process, but rather a
biologically occurring phenomena. Finally, we also observed a
signiﬁcant bias of standard bottom up approach for glycopeptide
quantitation which showed that about 60% of the O-glycosite is
occupied in these samples8. Previous studies have estimated
70–80% occupancy28, but our native MS data (Supplementary
Fig. 6) indicates that the occupancy is rather near complete
(90%). This further solidiﬁes the beneﬁt of our approach for
obtaining a true glycoproteoform proﬁles.
Discussion
We present a comprehensive analytic ﬂow of the complex gly-
coprotein EPO using a consecutive series of glycoengineered EPO
variants with and without speciﬁc glycan features, and we
demonstrate that native MS offers an excellent tool to quantitate
glycoproteoforms and discern even minor changes in glycan
structures. However, it is important to note that this type of data
can be acquired only on an orbitrap EMR instruments. We hope
that continuous advancements in instrument development will
enable other platforms to generate such data as well.
When compared with our previous study of glycoproteins22,
which combined middle-down and intact native MS analysis our
work represents a signiﬁcant advancement in two ways. Firstly, by
eliminating the need for middle-down analysis we no longer require
time-consuming sample preparation and glycopeptide enrichment
steps which shortened the analysis time from weeks to a single day.
Secondly, and more importantly, MS analysis of glycoproteins or
glycopeptides usually allows only for compositional proﬁling of
glycans attached to the backbone, i.e only the total mass of the
glycan attached can be deduced, but information about underlying
structure remains elusive. However in this study by combining the
glyoengineering efforts with native MS we were able to move
beyond compositional proﬁling of glycans and discern glycan
brancing vs. polyLacNAc elongation isomerism. We forsee that with
this methodology it will ultimately become feasible to completely
deconstruct a given glycosylation proﬁle of other glycoproteins.
Thus, native MS is an excellent tool for screening consistency in
glycoprotein products as well as providing a much-needed rapid
proﬁling tool for selection of cell clones during cell line develop-
ments for recombinant therapeutics. Moreover, it will become
increasingly more important to study divergence between biosimi-
lars and originators as well as different biosimilars of the same
originator product29 that arises from the modiﬁcations in the
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production processes during the product lifecycle30 where native
MS would prove especially advantageous.
Methods
EPO samples. Recombinant human EPO was produced in a panel of gene engi-
neered CHO cell lines as previously described8. CHO media, supplements and
other reagents were obtained from Sigma– Aldrich unless otherwise speciﬁed. CHO
cells were maintained as suspension cultures in CHO CD Fusion serum-free media,
supplemented with 4mM L-glutamine in 50 mL TPP TubeSpin® Bioreactors with
200 rpm or 100 ml in Corning 500 ml culture bottle with 130 rpm (Infors, USA) at
36.5 °C and 5% CO2 in air. Gene engineering was performed in CHOZN GS−/−
cells (Sigma-Aldrich) or in CHO-K1 (ATCC) by ZFN mediated KO (mgat1/3/4 A/
4B/5, st3gal4/6, B3gnt1/2, B4galt3/4, cosmc) and by site-directed ZFN mediated KI
using the ObLiGaRe strategy, as previously described8. Two engineering events
were performed with TALENs (mgat2) or CRISPR/Cas9 (fut8). Brieﬂy, CHO cells
were transfected with 2 μg of each ZFNs or TALENs tagged with GFP/Crimson,
and for KI with additional 5 μg donor plasmid, using Amaxa Nucleofector 2B
(Lonza, Amaxa kit V, U24). After transfection cells were enriched by FACS and the
pool after 1–2 weeks was further single cell sorted to 96 well plates on a BD
FACSARIA III cell sorter. Clones were screened by Indel Detection by Amplicon
Analysis (IDAA) and indels further veriﬁed by Sanger sequencing31. Targeted gene
KI clones were screened by immunocytology with monoclonal antibodies to the
introduced enzymes and further veriﬁed by junction PCR. Expression constructs
containing the entire coding sequence of human EPO cloned into pcDNA3.1/myc-
His (C-terminal tags) respectively, were synthesized by Genewiz, USA, and stable
expression of EPO was established in the gene engineered clones by transfection of
the plasmid DNA and Zeocin selection. EPO is a 193 amino acid protein with N-
glycans at Asn51, Asn65, and Asn110, and O-glycan at Ser153. His-tagged
recombinant human EPO was puriﬁed by nickel afﬁnity puriﬁcation (Invitrogen,
US). Media was mixed 3:1 (v/v) in 4x binding buffer (200 mM Tris, pH 8.0, 1.2 M
NaCl) and applied to 0.3 ml packed NiNTA agarose (Invitrogen), pre-equilibrated
in binding buffer (50 mM Tris, pH 8.0, 300 mM NaCl). The column was washed
with binding buffer and then bound protein was eluted with binding buffer with
additional 250 mM imidazole. Fractions containing EPO were determined by SDS-
PAGE and further puriﬁed on a reverse-phase HPLC puriﬁcation with a Jupiter C4
column (5 µm, 300 Å, column 250 × 4.6 mm) (Phenomenex), using 0.1% tri-
ﬂuoroacetic acid and a gradient of 10–100% acetonitrile. Purity of proteins was
evaluated by Coomassie SDS-PAGE and proteins were quantiﬁed by BCA Protein
Assay Kit (Thermo Scientiﬁc, Rockford, US).
Sample preparation for native MS analysis. 20 μg of each EPO sample was
buffer exchanged into 150 mM aqueous ammonium acetate (pH 7.5) by ultra-
ﬁltration (vivaspin500, Sartorius Stedim Biotech, Germany) with a 10 kDa cut-off
ﬁlter. Concentration was adjusted to 5 μM and 4 μL was used for native MS ana-
lysis. Part of the EPO samples were treated with 0.02 U of sialidase (Roche, IN,
USA) or four units of PNGase F (Roche, IN, USA) and incubated at room tem-
perature overnight. Following the incubation EPO samples were buffer exchanged
once more into 150 mM aqueous ammonium acetate (pH 7.5) before native MS
analysis.
Native MS analysis. Samples were analyzed on a modiﬁed Exactive Plus Orbitrap
instrument with extended mass range (EMR) (Thermo Fisher Scientiﬁc, Bremen)
using a standard m/z range of 500–10,000. The voltage offsets on transport multi-
poles and ion lenses were manually tuned to achieve optimal transmission of
protein ions at elevated m/z. Nitrogen was used in the HCD cell at a gas pressure of
6 × 10−10 bar. MS parameters used: spray voltage 1.2–1.3 V, source fragmentation
and collision energy were varied from 5–30 to achieve optimal desolvation, and
resolution (at m/z 200) of 17,500. The instrument was mass calibrated in 500–5000
m/z range using CsI clusters as described previously19.
Data analysis. Average masses of Hexose (Hex, 162.1424), N-acetylhexosamine
(HexNAc, 203.1950), fucose (F,146.1430) and sialic acid (291.2579) were used for
PTM annotations. Based on the known backbone mass of EPO and biosynthetic
pathway of N-glycosylation a matrix of possible glycoproteoforms was constructed.
This matrix was then used to annotate raw spectra of EPOs and the annotation was
considered correct if the corresponding proteoform could be found in at least 3
consecutive charge states. Raw spectra were then further deconvoluted to zero-charge
by Intact Mass software32 (Protein Metrics, CA, USA) using default settings, except
for the mass range, which was adjusted based on the minimum and maximum mass
proteoforms identiﬁed directly from the raw spectra to minimize the presence of
artiﬁcial peaks. For quantitation of proteoforms, intensities were extracted directly
from raw spectra and were summed across the identiﬁed charge states.
Clustering analysis. Raw spectra were pre-processed by binning the data points
for each peak into deﬁned m/z range. Bin size of 0.1m/z was chosen as an optimal
bin size that maximizes the differentiation of partially overlapping peaks between
different raw spectra. Hierarchical clustering (complete linkage algorithm) using
Pearson correlation was used to identify spectra with similar glycosylation features.
Corresponding similarity matrix was produced using the freely available R package
corrplot (version 0.84).
Data availability. The data and the raw ﬁles that support the ﬁndings of this study
are available on request from the corresponding author (A.J.R.H.). All cell lines are
available on request under a standard MTA with University of Copenhagen for
academic research purposes.
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